Close
Achema middle east
swop processing & packaging

Pfizer To Buy 8.1% Equity In Valneva, A French Vaccine Firm

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Pfizer, the world’s largest pharmaceutical company, has decided to invest 90.5 million euros ($95.24 million) in Valneva, a French vaccine company, as the businesses reported further advancements in their Lyme disease collaboration.

Pfizer will purchase a 9.49 euro per share interest in Valneva, which is also developing the COVID-19 vaccine, through a restricted capital increase. The profits from Pfizer’s equity investment will be used by Valneva to enhance its Lyme disease Phase 3 development commitment.

Valneva and Pfizer also revised the conditions of their collaboration and licence agreement for the Lyme disease vaccine candidate VLA15, which they announced on April 30, 2020. Pfizer’s investment in Valneva exemplifies the excellence of their work together over the last 2 years and is a wide acceptance of Valneva’s vaccine expertise, said Thomas Lingelbach, CEO of Valneva.

Pfizer aims to begin the Phase 3 research of VLA15 in the third quarter of 2022, as previously stated on April 26, 2022. Valneva will now finance 40% of the remaining shared development expenditures under the amended agreement, up from 30% previously. Valneva will get tiered royalties ranging from 14% to 22% from Pfizer. According to the companies, the royalties will be supplemented by up to $100 million in milestone payments to Valneva based on cumulative sales.

Latest stories

Related stories

Russia, Vietnam Collaborate on Biopharma Technology Transfer

Russia and Vietnam have gone on to officially formalize...

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »